GB0721095D0 - Pharmaceutical compounds - Google Patents

Pharmaceutical compounds

Info

Publication number
GB0721095D0
GB0721095D0 GBGB0721095.8A GB0721095A GB0721095D0 GB 0721095 D0 GB0721095 D0 GB 0721095D0 GB 0721095 A GB0721095 A GB 0721095A GB 0721095 D0 GB0721095 D0 GB 0721095D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical compounds
pharmaceutical
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0721095.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramed Ltd
Original Assignee
Piramed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramed Ltd filed Critical Piramed Ltd
Priority to GBGB0721095.8A priority Critical patent/GB0721095D0/en
Publication of GB0721095D0 publication Critical patent/GB0721095D0/en
Priority to PCT/GB2008/003621 priority patent/WO2009053715A1/en
Priority to CA2701276A priority patent/CA2701276A1/en
Priority to US12/739,435 priority patent/US8293735B2/en
Priority to JP2010530548A priority patent/JP5675360B2/ja
Priority to EP08842778.6A priority patent/EP2205610B1/en
Priority to CN2008801126921A priority patent/CN101868464B/zh
Priority to ES08842778.6T priority patent/ES2442501T3/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0721095.8A 2007-10-26 2007-10-26 Pharmaceutical compounds Ceased GB0721095D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0721095.8A GB0721095D0 (en) 2007-10-26 2007-10-26 Pharmaceutical compounds
PCT/GB2008/003621 WO2009053715A1 (en) 2007-10-26 2008-10-27 Thienopyrimidiene derivatives as pi3k inhibitors
CA2701276A CA2701276A1 (en) 2007-10-26 2008-10-27 Thienopyrimidiene derivatives as pi3k inhibitors
US12/739,435 US8293735B2 (en) 2007-10-26 2008-10-27 Thienopyrimidine derivatives as P13K inhibitors
JP2010530548A JP5675360B2 (ja) 2007-10-26 2008-10-27 Ｐｉ３ｋ阻害剤としてのチエノピリミジエン誘導体
EP08842778.6A EP2205610B1 (en) 2007-10-26 2008-10-27 Thienopyrimidiene derivatives as pi3k inhibitors
CN2008801126921A CN101868464B (zh) 2007-10-26 2008-10-27 作为pi3抑制剂的噻吩并嘧啶衍生物
ES08842778.6T ES2442501T3 (es) 2007-10-26 2008-10-27 Derivados de tienopirimidina como inhibidores de PI3K

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0721095.8A GB0721095D0 (en) 2007-10-26 2007-10-26 Pharmaceutical compounds

Publications (1)

Publication Number Publication Date
GB0721095D0 true GB0721095D0 (en) 2007-12-05

Family

ID=38830047

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0721095.8A Ceased GB0721095D0 (en) 2007-10-26 2007-10-26 Pharmaceutical compounds

Country Status (8)

Country Link
US (1) US8293735B2 (OSRAM)
EP (1) EP2205610B1 (OSRAM)
JP (1) JP5675360B2 (OSRAM)
CN (1) CN101868464B (OSRAM)
CA (1) CA2701276A1 (OSRAM)
ES (1) ES2442501T3 (OSRAM)
GB (1) GB0721095D0 (OSRAM)
WO (1) WO2009053715A1 (OSRAM)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
SI1912675T1 (sl) 2005-07-25 2014-07-31 Emergent Product Development Seattle, Llc zmanjšanje števila celic B z uporabo molekul, ki se specifično vežejo na CD37 in CD20
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
WO2009085230A1 (en) 2007-12-19 2009-07-09 Amgen Inc. Inhibitors of pi3 kinase
SG189772A1 (en) 2008-04-11 2013-05-31 Trubion Pharmaceuticals Inc Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
TWI378933B (en) 2008-10-14 2012-12-11 Daiichi Sankyo Co Ltd Morpholinopurine derivatives
SG182247A1 (en) * 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
SG175708A1 (en) 2009-05-27 2011-12-29 Genentech Inc Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
EP3399026B1 (en) 2010-06-14 2024-06-26 The Scripps Research Institute Reprogramming of cells to a new fate
MX2013006858A (es) 2010-12-16 2013-07-29 Hoffmann La Roche Compuesto triciclicos inhibidores de la pi3k y metodos de uso.
EP2548864B1 (en) 2011-07-22 2014-02-19 Université Joseph Fourier Novel bis-indolic derivatives, a process for preparing the same and their uses as a drug
RU2014149145A (ru) 2012-05-23 2016-07-20 Ф. Хоффманн-Ля Рош Аг Композиции и способы получения и применения эндодермальных клеток и гепатоцитов
BR112015002493A8 (pt) * 2012-08-30 2019-07-30 Hoffmann La Roche composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, kit e uso de um composto”
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
UA126278C2 (uk) 2015-09-21 2022-09-14 Аптево Рісьорч Енд Девелопмент Ллс Поліпептиди, які зв'язують cd3
US10591000B2 (en) * 2016-05-24 2020-03-17 Means Industries, Inc. One-way clutch assembly and coupling member for therein wherein locking member dynamics with respect to strut laydown speed are enhanced
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3903786A4 (en) * 2018-12-27 2022-09-28 Holosmedic NEW COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THEM FOR ENHANCING ANTICANCER ACTIVITY
KR102338609B1 (ko) * 2019-05-20 2021-12-14 보령제약 주식회사 피리도-피리미딘 화합물 및 이를 유효성분으로 포함하는 pi3k 관련 질환의 예방 또는 치료용 약학적 조성물
EP3972963A1 (en) 2019-05-21 2022-03-30 Bayer Aktiengesellschaft Identification and use of kras inhibitors
BR112021024101A2 (pt) * 2019-05-31 2022-02-08 Ideaya Biosciences Inc Derivados de tiadiazolila como inibidores de dna polimerase teta
EP4053127A4 (en) * 2019-10-31 2023-11-29 Holosmedic NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CANCER
CN112920199B (zh) * 2020-06-02 2023-02-03 四川大学 一种哌嗪酮取代物或其衍生物及其制备方法和应用、药物组合物
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1470356A1 (de) 1964-01-15 1970-04-30 Thomae Gmbh Dr K Neue Thieno[3,2-d]pyrimidine und Verfahren zu ihrer Herstellung
BE754606A (fr) 1969-08-08 1971-02-08 Thomae Gmbh Dr K Nouvelles 2-aminoalcoylamino-thieno(3,2-d)pyrimidines et leurs procedesde fabrication
BE759493A (fr) 1969-11-26 1971-05-25 Thomae Gmbh Dr K Nouvelles 2-(5-nitro-2-furyl)-thieno(3,2-d) pyrimidines et procedes pour les fabriquer
US3763156A (en) 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
RO62428A (fr) 1971-05-04 1978-01-15 Thomae Gmbh Dr K Procede pour la preparation des thyeno-(3,2-d)-pyrimidines
CH592668A5 (OSRAM) 1973-10-02 1977-10-31 Delalande Sa
GB1570494A (en) 1975-11-28 1980-07-02 Ici Ltd Thienopyrimidine derivatives and their use as pesticides
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
ES2356886T3 (es) 1998-03-31 2011-04-14 Kyowa Hakko Kirin Co., Ltd. Compuestos heterocíclicos nitrogenados.
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
WO2001083456A1 (en) 2000-04-27 2001-11-08 Yamanouchi Pharmaceutical Co., Ltd. Condensed heteroaryl derivatives
US20020156601A1 (en) * 2001-04-19 2002-10-24 Tu Kevin Hsiaohsu Event monitoring and detection system
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
ES2217956B1 (es) 2003-01-23 2006-04-01 Almirall Prodesfarma, S.A. Nuevos derivados de 4-aminotieno(2,3-d)pirimidin-6-carbonitrilo.
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
GB0520657D0 (en) 2005-10-11 2005-11-16 Ludwig Inst Cancer Res Pharmaceutical compounds
BRPI0710874A2 (pt) 2006-04-26 2012-02-14 Hoffmann La Roche compostos de tienopirimidina, processos de produção dos referidos compostos, composições farmacêuticas contendo os mesmos, kit, produto, e usos dos compostos
MX2008013582A (es) 2006-04-26 2009-01-19 Hoffmann La Roche Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
KR101402474B1 (ko) 2006-04-26 2014-06-19 제넨테크, 인크. 포스포이노시티드 3-키나제 억제제 화합물 및 이를 포함하는 약학적 조성물
EP2041139B1 (en) 2006-04-26 2011-11-09 F. Hoffmann-La Roche AG Pharmaceutical compounds
GB0608820D0 (en) 2006-05-04 2006-06-14 Piramed Ltd Pharmaceutical compounds
TWI499420B (zh) 2006-12-07 2015-09-11 Hoffmann La Roche 肌醇磷脂３-激酶抑制劑化合物及使用方法
KR101507182B1 (ko) 2006-12-07 2015-03-30 제넨테크, 인크. 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
CA2699202C (en) 2007-09-12 2016-09-27 F. Hoffmann-La Roche Ag Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
CA2704711C (en) 2007-09-24 2016-07-05 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
US20110230464A1 (en) 2007-10-26 2011-09-22 Paul Goldsmith Purine derivatives useful as p13 kinase inhibitors
KR20110042153A (ko) 2008-05-30 2011-04-25 제넨테크, 인크. 퓨린 ｐｉ３ｋ 억제 화합물 및 사용 방법
SG175708A1 (en) 2009-05-27 2011-12-29 Genentech Inc Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
SG182247A1 (en) 2009-05-27 2012-08-30 Hoffmann La Roche Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use

Also Published As

Publication number Publication date
JP2011500774A (ja) 2011-01-06
CN101868464B (zh) 2013-11-13
EP2205610B1 (en) 2013-11-20
US20110021496A1 (en) 2011-01-27
JP5675360B2 (ja) 2015-02-25
EP2205610A1 (en) 2010-07-14
WO2009053715A8 (en) 2010-06-03
CN101868464A (zh) 2010-10-20
CA2701276A1 (en) 2009-04-30
WO2009053715A1 (en) 2009-04-30
US8293735B2 (en) 2012-10-23
ES2442501T3 (es) 2014-02-11

Similar Documents

Publication Publication Date Title
GB0709031D0 (en) Pharmaceutical compounds
IL201366A0 (en) Pharmaceutical compounds
GB0721095D0 (en) Pharmaceutical compounds
ZA201104336B (en) Pharmaceutical compounds
GB0707087D0 (en) Pharmaceutical compounds
GB0816372D0 (en) Pharmaceutical compounds
GB0820819D0 (en) Pharmaceutical compounds
GB0801416D0 (en) Pharmaceutical compounds
GB0816371D0 (en) Pharmaceutical compounds
GB0704932D0 (en) Pharmaceutical compounds
GB0725214D0 (en) Pharmaceutical compounds
GB0812969D0 (en) Pharmaceutical compounds
GB0721669D0 (en) Pharmaceutical compounds
PT2271618E (pt) Compostos farmacêuticos
GB0816370D0 (en) Pharmaceutical compounds
GB0810857D0 (en) Pharmaceutical compounds
GB0718045D0 (en) Pharmaceutical compound
GB0608176D0 (en) Pharmaceutical Compounds
GB0608184D0 (en) Pharmaceutical compounds
GB0608175D0 (en) Pharmaceutical Compounds
GB0608264D0 (en) Pharmaceutical compounds
GB0707611D0 (en) Pharmaceutical compounds
GB0716798D0 (en) Pharmaceutical compounds
GB0711346D0 (en) Pharmaceutical compounds
GB0707613D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
COOA Change in applicant's name or ownership of the application
AT Applications terminated before publication under section 16(1)